Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71
This prespecified analysis from AZALEA-TIMI 71 demonstrated that prior oral anticoagulation (OAC) experience modifies bleeding risk in atrial fibrillation. The factor XI inhibitor abelacimab consistently reduced bleeding irrespective of prior OAC experience, with potentially greater absolute benefit among OAC-naïve patients. CT# NCT04755283.
Authors
- Róbert Gábor Kiss (ORCID: https://orcid.org/0000-0003-0514-7530)
- Erica L. Goodrich (ORCID: https://orcid.org/0000-0002-8541-264X)
- Siddharth M. Patel (ORCID: https://orcid.org/0000-0002-4637-4361)
- Sanobar Parkar
- Dan Bloomfield
- C T Ruff
- David A Morrow
- Bruce Hug (ORCID: https://orcid.org/0009-0001-3819-2779)
- Jeffrey I Weitz
- Andre Maurice Small (ORCID: https://orcid.org/0009-0007-9775-398X)
- Wojciech Wojakowski
- Shaun G Goodman (ORCID: https://orcid.org/0000-0001-8068-2440)
- Boyoung Joung (ORCID: https://orcid.org/0000-0001-9036-7225)
- Marc S Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Shih-Ann Chen (ORCID: https://orcid.org/0000-0001-9085-0823)
- Robert P Giugliano
Institutions
- Semmelweis University (HU)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Harvard University (US)
- Medical University of Silesia (PL)
- University of Toronto (CA)
- Yonsei University (KR)
- Taipei Veterans General Hospital (TW)
- DecImmune Therapeutics (United States) (US)
- Sarepta Therapeutics (United States) (US)
- Thrombolysis in Myocardial Infarction Study Group (US)
- McMaster University (CA)
Publication Details
- Journal
- Blood
- Published
- 2026-05-29
- DOI
- https://doi.org/10.1182/blood.2026033829
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00